{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:19:35Z","timestamp":1793884775157,"version":"4.7.0"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2021,8,18]]},"abstract":"<jats:p>\n            <jats:named-content content-type=\"genus-species\">Stenotrophomonas maltophilia<\/jats:named-content>\n            is intrinsically resistant to many beta-lactam antibiotics, including carbapenems, and is resistant to aminoglycosides, which limits the therapeutic repertoire for managing\n            <jats:named-content content-type=\"genus-species\">S. maltophilia<\/jats:named-content>\n            infections. Additionally, employing automated\n            <jats:italic>in vitro<\/jats:italic>\n            susceptibility testing of\n            <jats:named-content content-type=\"genus-species\">S. maltophilia<\/jats:named-content>\n            is challenging because commercial test systems\u2019 performance is limited (A.\n          <\/jats:p>","DOI":"10.1128\/jcm.01094-21","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T15:47:58Z","timestamp":1625068078000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":37,"title":["Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies"],"prefix":"10.1128","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-5191","authenticated-orcid":true,"given":"Daniel D.","family":"Rhoads","sequence":"first","affiliation":[{"name":"Pathology and Laboratory Medicine Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0279-3"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.ARBA-0005-2017"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz116"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2649-5"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.11.008"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00654-21"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02631-20"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0732-8893(98)00089-3"},{"key":"e_1_3_1_10_2","unstructured":"FDA. 2009. Guidance for industry and FDA\u2013class II special controls guidance document: antimicrobial susceptibility test (AST) systems. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/media\/88069\/download"},{"key":"e_1_3_1_11_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2012. Stenotrophomonas maltophilia . https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/General_documents\/S_maltophilia_EUCAST_guidance_note_20120201.pdf"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy293"},{"key":"e_1_3_1_13_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2021","unstructured":"CLSI. 2021. Performance standards for antimicrobial susceptibility testing, 31st ed. Clinical and Laboratory Standards Institute.","edition":"31"},{"key":"e_1_3_1_14_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2021. Breakpoint tables for interpretation of MICs and zone diameters version 11.0."},{"key":"e_1_3_1_15_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2021. Delafloxacin rationale document version 2.0. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Levofloxacin_Rationale_Document_2.0_20210101.pdf"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00714-15"},{"key":"e_1_3_1_17_2","volume-title":"Performance standards for antimicrobial disk susceptibility tests","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. Performance standards for antimicrobial disk susceptibility tests, 13th ed. Clinical and Laboratory Standards Institute.","edition":"13"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01603-19"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01485-07"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks088"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00777-17"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.11.020"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01390-18"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa121"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00064-16"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01436-20"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01558-19"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.13831"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1155"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01094-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01094-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T12:57:00Z","timestamp":1646485020000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.01094-21"}},"subtitle":[],"editor":[{"given":"Patricia J.","family":"Simner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,8,18]]}},"alternative-id":["10.1128\/JCM.01094-21"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01094-21","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"2021-08-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01094-21"}}